General Information of Drug (ID: DMSKJ1X)

Drug Name
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9859248
TTD Drug ID
DMSKJ1X

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Preclinical Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PD-0183812 DMWYP86 Retinoblastoma 2D02.2 Terminated [2]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 Discovery agent N.A. Investigative [3]
3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT Discovery agent N.A. Investigative [3]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY Discovery agent N.A. Investigative [3]
BMS-536924 DMXJB4N Discovery agent N.A. Investigative [4]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N Discovery agent N.A. Investigative [3]
aloisine A DM5U1LN Discovery agent N.A. Investigative [5]
3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol DMJZK40 Discovery agent N.A. Investigative [1]
(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime DMGXRSZ Discovery agent N.A. Investigative [6]
(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime DMZ0V6G Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ABT-263 DMNE56X Myelofibrosis 2A20.2 Phase 3 [7]
Briciclib DMK7BND Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 Discovery agent N.A. Investigative [3]
3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT Discovery agent N.A. Investigative [3]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY Discovery agent N.A. Investigative [3]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N Discovery agent N.A. Investigative [3]
7-hydroxycoumarin DMTMNO7 Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 7 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VFEDEOUBYBLDKN-AAFJCEBUSA-N DMH9ION N. A. N. A. Patented [10]
XHPNYYOUZWOWNT-PYUWXLGESA-N DM5Q93Y N. A. N. A. Patented [10]
AGGGWZCOULSEER-PYUWXLGESA-N DM2L83Y N. A. N. A. Patented [10]
BALANOL DMDLN9E N. A. N. A. Terminated [11]
Ro-4396686 DM5DMCH Discovery agent N.A. Investigative [12]
NM-PP1 DMS8H5Q Discovery agent N.A. Investigative [13]
ISIS 102633 DMWT7BK Discovery agent N.A. Investigative [14]
ISIS 102604 DMZ6X9B Discovery agent N.A. Investigative [14]
ISIS 102619 DMXH9IT Discovery agent N.A. Investigative [14]
ISIS 102462 DMXNC0B Discovery agent N.A. Investigative [14]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flavopiridol DMKSUOI Acute myeloid leukaemia 2A60 Phase 2 [7]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [15]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [16]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [17]
BTX-A51 DMC8XHQ Advanced solid tumour 2A00-2F9Z Phase 1 [18]
CYC065 DM9ODT6 Lymphoma 2A80-2A86 Phase 1 [7]
AZD4573 DMOYPTK Haematological malignancy 2B33.Y Phase 1 [7]
TP-1287 DM3Z07E Solid tumour/cancer 2A00-2F9Z Phase 1 [19]
VIP-152 DMBQ5OL Chronic lymphocytic leukaemia 2A82.0 Phase 1 [20]
AZD7503 DM8XJD2 Non-alcoholic steatohepatitis DB92.1 Phase 1 [21]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CX-4945 DMWE7B9 Coronavirus infection 1D92 Phase 2 [7]
BALANOL DMDLN9E N. A. N. A. Terminated [22]
EMODIN DMAEDQG Coronavirus Disease 2019 (COVID-19) 1D6Y Terminated [23]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [23]
ELLAGIC ACID DMX8BS5 Discovery agent N.A. Investigative [23]
APIGENIN DMI3491 Discovery agent N.A. Investigative [23]
PMID24900749C1a DMZPUSO Discovery agent N.A. Investigative [24]
AdoC(Dpr)2AlaArg6 DM2TWSZ Discovery agent N.A. Investigative [25]
PMID22115617C2c DMX5UKA Discovery agent N.A. Investigative [26]
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole DM3JB6S Discovery agent N.A. Investigative [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cyclin A2 (CCNA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PD-0183812 DMWYP86 Retinoblastoma 2D02.2 Terminated [2]
aloisine A DM5U1LN Discovery agent N.A. Investigative [5]
3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol DMJZK40 Discovery agent N.A. Investigative [1]
MERIOLIN 8 DM0E95B Discovery agent N.A. Investigative [27]
2,5-dichloro-N-p-tolylthiophene-3-sulfonamide DMU5J8Y Discovery agent N.A. Investigative [28]
Purvalanol A DMNQ7TM Discovery agent N.A. Investigative [13]
MERIOLIN 1 DMJT93H Discovery agent N.A. Investigative [27]
MERIOLIN 4 DMIJMZQ Discovery agent N.A. Investigative [27]
MERIOLIN 6 DMW5AXC Discovery agent N.A. Investigative [27]
MERIOLIN 5 DMGVLR0 Discovery agent N.A. Investigative [27]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BVD-523 DMNB4XK Melanoma 2C30 Phase 2 [29]
HH2710 DM0C5MV Solid tumour/cancer 2A00-2F9Z Phase 1/2 [30]
ASTX029 DMVZXIA Solid tumour/cancer 2A00-2F9Z Phase 1/2 [31]
VAN-10-4-eluting stent DM3ZW6A Artery stenosis BD52 Phase 1 [32]
GDC-0994 DMFC2OY Solid tumour/cancer 2A00-2F9Z Phase 1 [33]
JSI-1187 DMVJWBS Solid tumour/cancer 2A00-2F9Z Phase 1 [34]
LY3214996 DMFDAY7 Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
CHIR-99021 DMB8MNU Allergic inflammation 4A80-4A85 Patented [35]
COR-D DMLXMCB T-cell leukaemia 2A90 Preclinical [36]
SB220025 DMSBUET Arthritis FA20 Terminated [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Checkpoint kinase-1 (CHK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY2603618 DMCXRZF Pancreatic cancer 2C10 Phase 2 [38]
UCN-01 DMUNJZB Non-small-cell lung cancer 2C25.Y Phase 2 [39]
SCH-900776 DM67EMK Solid tumour/cancer 2A00-2F9Z Phase 2 [40]
LY2606368 DM4XMF7 Ovarian cancer 2C73 Phase 2 [7]
LY2880070 DMADEHZ Solid tumour/cancer 2A00-2F9Z Phase 1/2 [41]
RG7741 DMK6P9J Lymphoma 2A80-2A86 Phase 1 [42]
GDC-0425 DMDZ26X Lymphoma 2A80-2A86 Phase 1 [43]
AZD7762 DM1FW0C Solid tumour/cancer 2A00-2F9Z Phase 1 [44]
MK-8776 DMAS1RB Hodgkin lymphoma 2B30 Phase 1 [45]
Diamidothiazole derivative 1 DM02V5Q N. A. N. A. Patented [46]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [47]
Bosutinib DMTI8YE Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [48]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [49]
Adenosine triphosphate DM79F6G Malnutrition 5B50-5B71 Approved [50]
Saracatinib DMBLHGP Hematologic tumour 2B33.Y Phase 2 [51]
Flumatinib DM0G5O6 Chronic myelogenous leukaemia 2A20.0 Phase 2 [52]
DCC-2036 DMJKFNU Chronic myeloid leukaemia 2A20 Phase 1/2 [53]
ISIS-CRP DMQDUG4 Cardiovascular disease BA00-BE2Z Phase 1 [54]
KW-2449 DMFO7RP Acute myeloid leukaemia 2A60 Phase 1 [55]
IkT-148009 DMMJ9HY Parkinson disease 8A00.0 Phase 1 [56]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ozagrel DMIGKA1 Xerophthalmia 5B55.Y Phase 4 [57]
Losmapimod DMIL37Z Acute coronary syndrome BA41 Phase 3 [57]
VX-702 DMKJDR6 Coronary artery disease BA80 Phase 2a [58]
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [59]
Dilmapimod DMBYJ92 Acute lung injury NB32.3 Phase 2 [57]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [60]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [60]
PMID25991433-Compound-L2 DM58UO9 N. A. N. A. Patented [60]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [60]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [60]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Capivasertib DM9SKW8 Breast cancer 2C60-2C65 Approved [7]
Enzastaurin DM5H0R9 Diffuse large B-cell lymphoma 2A81 Phase 3 [7]
GDC-0068 DMWBZJD Breast cancer 2C60-2C65 Phase 3 [7]
CI-1033 DMSI8N3 Lymphoma 2A80-2A86 Phase 2 [48]
CMX-2043 DMPSCVY Cardiac disease BA00-BE2Z Phase 2 [61]
ARQ 092 DM5WK0J Proteus syndrome LD2C Phase 2 [62]
GSK2110183 DMZHB37 leukaemia 2A60-2B33 Phase 2 [63]
RX-0201 DMTBAV3 Pancreatic cancer 2C10 Phase 2 [64]
PTX-200 DM0ZIT2 Breast cancer 2C60-2C65 Phase 2 [7]
Triciribine prodrug DMBN1XS Solid tumour/cancer 2A00-2F9Z Phase 1/2 [63]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [15]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [48]
PHA848125 DMS2Q9G Thymic cancer 2C27 Phase 2 [65]
TG02 DMZFIGQ Anaplastic astrocytoma 2A00.0 Phase 1/2 [66]
NUV-422 DMQJQNT Malignant glioma 2A00.0 Phase 1/2 [67]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [16]
FN-1501 DM7BMD6 Solid tumour/cancer 2A00-2F9Z Phase 1 [68]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [15]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [69]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [17]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AMO-02 DMJRU3A Myotonic dystrophy 8C71.0 Phase 2/3 [70]
LY2090314 DMTBFE4 Acute myeloid leukaemia 2A60 Phase 2 [71]
Lithium DMZ3OU6 Bipolar disorder 6A60 Phase 2 [72]
Tideglusib DME4LA1 Alzheimer disease 8A20 Phase 2 [73]
9-ING-41 DM57TY3 Myelofibrosis 2A20.2 Phase 2 [74]
Neu-120 DMXKOUC Parkinson disease 8A00.0 Phase 1/2 [75]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [76]
CHIR-99021 DMB8MNU Allergic inflammation 4A80-4A85 Patented [35]
TDZD-8 DMG6Q45 Malignant glioma 2A00.0 Patented [77]
AR-A014418 DMUPN01 Ovarian cancer 2C73 Patented [78]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BALANOL DMDLN9E N. A. N. A. Terminated [11]
Ro-4396686 DM5DMCH Discovery agent N.A. Investigative [12]
[3H]cAMP DMZRQU7 Discovery agent N.A. Investigative [37]
AdoC(Dpr)2AlaArg6 DM2TWSZ Discovery agent N.A. Investigative [25]
AdcAhxArg4NH(CH2)6NH2 DMSYMRJ Discovery agent N.A. Investigative [79]
AdcAhxArg4Lys-PEGOMe DMQ2C8X Discovery agent N.A. Investigative [79]
AdoC(GABA)Arg6 DMMWNPT Discovery agent N.A. Investigative [25]
AdcAhxArg4Lys(biotin)-PEG-OMe DMZYJHV Discovery agent N.A. Investigative [79]
AdoC(Aun)Arg6 DMDLHAB Discovery agent N.A. Investigative [25]
AdoCGlyArg6 DMVQJP0 Discovery agent N.A. Investigative [25]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apremilast DMTWS9E Psoriasis vulgaris EA90 Approved [80]
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [81]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [82]
Ribociclib Succinate DM9CIUW Breast cancer 2C60-2C65 Approved [83]
Trilaciclib DMP5A4T Small-cell lung cancer 2C25.Y Approved [84]
LEE011 DMMX75K Breast cancer 2C60-2C65 Phase 3 [85]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [48]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [15]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [86]
G1T38 DMQO2IT Breast cancer 2C60-2C65 Phase 2 [7]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BALANOL DMDLN9E N. A. N. A. Terminated [11]
Ro-4396686 DM5DMCH Discovery agent N.A. Investigative [12]
PMID20005102C1 DMMESBW Discovery agent N.A. Investigative [87]
[3H]cAMP DMZRQU7 Discovery agent N.A. Investigative [88]
PMID19364658C33 DMSE1C3 Discovery agent N.A. Investigative [89]
BX-912 DMZA45C Discovery agent N.A. Investigative [90]
BX-795 DMRIMLJ Discovery agent N.A. Investigative [90]
chelerythrine DMCP1G9 Discovery agent N.A. Investigative [91]
PMID21742770C1 DME3JMH Discovery agent N.A. Investigative [92]
Rp-adenosine 3',5'-cyclic monophosphothioate triethylamine (Rp-cAMPS) DM1JWGH Discovery agent N.A. Investigative [93]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
M2698 DM3PVBJ Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
NNI-362 DMPCV65 Alzheimer disease 8A20 Phase 1 [94]
PF-4708671 DMO0892 Ulcerative colitis DD71 Clinical trial [95]
PMID27410995-Compound-Figure3c DMDQMZT N. A. N. A. Patented [96]
Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1 DM6O2Q9 N. A. N. A. Patented [96]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [97]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [98]
CI-1040 DMF3DZX Discovery agent N.A. Investigative [97]
KN-62 DMLZ89P Discovery agent N.A. Investigative [97]
Ro31-8220 DMDJLF0 Discovery agent N.A. Investigative [97]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
cAMP protein kinase type II-beta (PRKAR2B) TTW4Y2M KAP3_HUMAN Inhibitor [1]
Casein kinase II alpha (CSNK2A1) TTER6YH CSK21_HUMAN Inhibitor [1]
Checkpoint kinase-1 (CHK1) TTTU902 CHK1_HUMAN Inhibitor [1]
Cyclin A2 (CCNA2) TTAMQ62 CCNA2_HUMAN Inhibitor [1]
Cyclin-dependent kinase 2 (CDK2) TT7HF4W CDK2_HUMAN Inhibitor [1]
Cyclin-dependent kinase 4 (CDK4) TT0PG8F CDK4_HUMAN Inhibitor [1]
Cyclin-dependent kinase 9 (CDK9) TT1LVF2 CDK9_HUMAN Inhibitor [1]
Extracellular signal-regulated kinase 2 (ERK2) TT4TQBX MK01_HUMAN Inhibitor [1]
Fungal Protein kinase A (Fung ypkA) TTYVI76 Q56921_YEREN Inhibitor [1]
G1/S-specific cyclin-D1 (CCND1) TTFCJ7S CCND1_HUMAN Inhibitor [1]
G1/S-specific cyclin-E1 (CCNE1) TTCEJ4F CCNE1_HUMAN Inhibitor [1]
Glycogen synthase kinase-3 beta (GSK-3B) TTRSMW9 GSK3B_HUMAN Inhibitor [1]
PRKACA messenger RNA (PRKACA mRNA) TT5U49F KAPCA_HUMAN Inhibitor [1]
RAC-alpha serine/threonine-protein kinase (AKT1) TTWTSCV AKT1_HUMAN Inhibitor [1]
Ribosomal protein S6 kinase beta-1 (S6K1) TTG0U4H KS6B1_HUMAN Inhibitor [1]
Stress-activated protein kinase 2a (p38 alpha) TTQBR95 MK14_HUMAN Inhibitor [1]
Tyrosine-protein kinase ABL1 (ABL) TT3PJMV ABL1_HUMAN Inhibitor [1]

References

1 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
2 Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
3 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
4 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
5 Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
6 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Clinical pipeline report, company report or official report of Onconova.
9 Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin. Lung Cancer. 2001 Nov;34(2):185-94.
10 Purine derivatives. US8846696.
11 Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address;
12 Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
13 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
14 US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
15 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
16 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
17 Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
18 Clinical pipeline report, company report or official report of BioTheryX.
19 Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
20 VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia. 2023 Feb;37(2):326-338.
21 ClinicalTrials.gov (NCT05560607) An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants With Non-alcoholic Fatty Liver Disease. U.S.National Institutes of Health.
22 Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A. J Med Chem. 1996 Dec 20;39(26):5215-27.
23 Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
24 Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5.
25 Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
26 CK2alpha and CK2alpha' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur J Med Chem. 2012 Jan;47(1):345-50.
27 Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
28 Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
29 DOI: 10.1158/1538-7445.AM2015-4693
30 Clinical pipeline report, company report or official report of HaiHe Biopharma.
31 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
32 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
33 ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
34 National Cancer Institute Drug Dictionary (drug name JSI1187).
35 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
36 Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
37 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
38 Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
39 Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
40 Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
41 A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
42 National Cancer Institute Drug Dictionary (drug id 730054).
43 Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
44 Clinical pipeline report, company report or official report of AstraZeneca (2009).
45 Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095.
46 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
47 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
48 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
49 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
50 Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15.
51 Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
52 Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25.
53 Company report (Deciphera Pharmaceuticals: Tumor-Targeted Programs and Indications)
54 Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem. 2008 Mar 13;51(5):1252-9.
55 KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
56 The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease. Sci Transl Med. 2023 Jan 18;15(679):eabp9352.
57 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
58 Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
59 Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
60 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
61 Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
62 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
63 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
64 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
65 Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
66 Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
67 ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
68 Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
69 A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
70 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
71 Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
72 The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
73 Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
74 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
75 Company report (Neurim Pharmaceuticals)
76 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
77 Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
78 Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
79 Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
80 Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
81 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
82 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
83 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
84 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
85 Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
86 Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
87 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
88 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1694).
89 Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
90 Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
91 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
92 A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
93 Inhibition of protein kinase A activity interferes with long-term, but not short-term, memory of conditioned taste aversions. Behav Neurosci. 2002 Dec;116(6):1070-4.
94 Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease. Stem Cell Res Ther. 2021 Jan 13;12(1):59.
95 Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55.
96 Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
97 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
98 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.